source
- North Immunology to go public via reverse merger with Aethlon, targeting eczema marketNorth Immunology, an early-stage biotech developing a dual-acting antibody for eczema, announced plans to become a public company through a reverse merger with Aethlon Medical. The transaction wil…
- Novo and Orbis strike up to $1.4 billion partnership to develop oral peptide macrocycles for cardiometabolic diseaseNovo Pharmaceuticals has entered a partnership with fellow Danish firm Orbis Medicines that could be worth as much as $1.4 billion. The agreement includes upfront payments, downstream payouts and r…